DIA is a global association that mobilizes life science professionals from across all areas of expertise to engage with patients, peers and thought leaders in a neutral environment on the issues of today and the possibilities for tomorrow.
As a member-driven volunteer organization, professionals from more than 80 countries have engaged with DIA through our unparalleled membership network, educational offerings, and professional development opportunities.
To keep you at the forefront, DIA offers face-to-face, and online courses (including eLearning programs), certificate programs, and can provide learning for groups at your organization.
The world of healthcare is constantly changing. DIA events will help you stay on top of those changes. At DIA events, key stakeholders from multiple disciplines come together to share information and insights. New perspectives are explored. Career-enhancing relationships are nurtured.
| Date & Time (EST) | Title | Presenters |
|---|---|---|
| On Demand Only | The Value of Tokenizing Clinical Development Data for Real-World Evidence | - |
Retiring TGA Head Maps Australia’s Post-Pandemic Future July 17, 2023 2:57pm
In April 2023, Professor John Skerritt retired after 11 years of exemplary public service as deputy secretary of the Health Products Regulation Group and head of the Therapeutic Goods Administration in Australia. “What's really changed and what will persist after COVID? First, I think regulators have become a bit more comfortable in dealing with uncertainty. Uncertainty is the biggest challenge rather than benefit-risk,” he explains. “International regulatory collaboration became the basis...
View this post
Patient Engagement: Evolution of Who Knows What, Part 2 June 14, 2023 7:54am
In part two of this podcast, “ePatients” Dave deBronkart and Stacy Hurt (Patient Advocacy Ambassador, Parexel) discuss new opportunities in the future of patient engagement in clinical research and care with DIA GAM 2023 Patient Engagement track chair Pujita Vaidya. “This advent and acceleration of artificial intelligence (which should be augmented intelligence) and digital biomarkers should not replace the physician-patient relationship but enhance it,” Stacy explains. “Lastly: If you...
View this post
Patient Engagement: Evolution of Who Knows What, Part 1 June 12, 2023 8:13am
DIA GAM 2023 Patient Engagement track chair Pujita Vaidya discusses the definition, history, and current state of patient engagement in clinical research and care with cancer survivors and “ePatients” Dave deBronkart and Stacy Hurt (Patient Advocacy Ambassador, Parexel). “Many people were trained for generations to think of patients as poor people who just don't understand how to save their own lives. I'm here to tell you, we are not only eager to help but we're tired of being treated as c...
View this post
Australian Clinical Trials Alliance Part 2 – Future Projections March 27, 2023 8:36am
“Healthcare systems obviously have as their primary role the delivery of healthcare,” says Steve Webb, Australian Clinical Trials Alliance board chair. “But we can see big improvements in health outcomes, combined with substantially better financial performance of the healthcare system, if the healthcare system has the dual role of treating patients as well as generating evidence about the most effective treatment options to guide that care.”
View this post
ANVISA Explains Innovative Online Optimized Assessment Project March 14, 2023 9:52am
For regulators in Brazil, the pandemic’s aftermath includes a backlog of post-approval changes, delayed by emergency development of COVID-19 vaccines and therapies, related to biologic product quality. ANVISA’s new Online Optimized Assessment Project has significantly resolved these pending requests. “The pandemic had already enabled use of online tools for remote assessment of applications and virtual meetings between ANVISA and applicants, and also helped us be closer to other reference...
View this post
Australian Clinical Trials Alliance Part 1 – Current Perceptions March 6, 2023 2:26pm
“The pandemic had a substantial impact on community understanding of clinical trials. Having said that, the sort of ambient level of community knowledge of clinical trials is still substantially lower than it needs to be,” explains Australian Clinical Trials Alliance Board Chair Steve Webb. “Community awareness of the difference between evaluation of experimental interventions, about which relatively little is known regarding safety and effectiveness, compared with comparative effectivenes...
View this post
Head of Strategic Partnerships
DIA Global
Washington, District of Columbia
